509 related articles for article (PubMed ID: 32333898)
1. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial.
Traboulsee A; Greenberg BM; Bennett JL; Szczechowski L; Fox E; Shkrobot S; Yamamura T; Terada Y; Kawata Y; Wright P; Gianella-Borradori A; Garren H; Weinshenker BG
Lancet Neurol; 2020 May; 19(5):402-412. PubMed ID: 32333898
[TBL] [Abstract][Full Text] [Related]
2. Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder.
Yamamura T; Kleiter I; Fujihara K; Palace J; Greenberg B; Zakrzewska-Pniewska B; Patti F; Tsai CP; Saiz A; Yamazaki H; Kawata Y; Wright P; De Seze J
N Engl J Med; 2019 Nov; 381(22):2114-2124. PubMed ID: 31774956
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial.
Cree BAC; Kim HJ; Weinshenker BG; Pittock SJ; Wingerchuk DM; Fujihara K; Paul F; Cutter GR; Marignier R; Green AJ; Aktas O; Hartung HP; She D; Rees W; Smith M; Cimbora D; Katz E; Bennett JL;
Lancet Neurol; 2024 Jun; 23(6):588-602. PubMed ID: 38760098
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial.
Zhang C; Zhang M; Qiu W; Ma H; Zhang X; Zhu Z; Yang CS; Jia D; Zhang TX; Yuan M; Feng Y; Yang L; Lu W; Yu C; Bennett JL; Shi FD;
Lancet Neurol; 2020 May; 19(5):391-401. PubMed ID: 32333897
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial.
Tahara M; Oeda T; Okada K; Kiriyama T; Ochi K; Maruyama H; Fukaura H; Nomura K; Shimizu Y; Mori M; Nakashima I; Misu T; Umemura A; Yamamoto K; Sawada H
Lancet Neurol; 2020 Apr; 19(4):298-306. PubMed ID: 32199095
[TBL] [Abstract][Full Text] [Related]
6. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial.
Cree BAC; Bennett JL; Kim HJ; Weinshenker BG; Pittock SJ; Wingerchuk DM; Fujihara K; Paul F; Cutter GR; Marignier R; Green AJ; Aktas O; Hartung HP; Lublin FD; Drappa J; Barron G; Madani S; Ratchford JN; She D; Cimbora D; Katz E;
Lancet; 2019 Oct; 394(10206):1352-1363. PubMed ID: 31495497
[TBL] [Abstract][Full Text] [Related]
7. Satralizumab for the Treatment of Neuromyelitis Optica Spectrum Disorders.
Gao Y; Zhang B; Yang J
Ann Pharmacother; 2021 Sep; 55(9):1167-1171. PubMed ID: 33246373
[TBL] [Abstract][Full Text] [Related]
8. Exploring steroid tapering in patients with neuromyelitis optica spectrum disorder treated with satralizumab in SAkuraSky: A case series.
Yamamura T; Araki M; Fujihara K; Okuno T; Misu T; Guo YC; Hemingway C; Matsushima J; Sugaya N; Yamashita M; von Büdingen HC; Miyamoto K
Mult Scler Relat Disord; 2022 May; 61():103772. PubMed ID: 35537314
[TBL] [Abstract][Full Text] [Related]
9. Satralizumab: A Review in Neuromyelitis Optica Spectrum Disorder.
Fung S; Shirley M
CNS Drugs; 2023 Apr; 37(4):363-370. PubMed ID: 36933107
[TBL] [Abstract][Full Text] [Related]
10. Long-term Efficacy of Satralizumab in AQP4-IgG-Seropositive Neuromyelitis Optica Spectrum Disorder From SAkuraSky and SAkuraStar.
Kleiter I; Traboulsee A; Palace J; Yamamura T; Fujihara K; Saiz A; Javed A; Mayes D; Büdingen HV; Klingelschmitt G; Stokmaier D; Bennett JL
Neurol Neuroimmunol Neuroinflamm; 2023 Jan; 10(1):. PubMed ID: 36724181
[TBL] [Abstract][Full Text] [Related]
11. SAkuraBONSAI: Protocol design of a novel, prospective study to explore clinical, imaging, and biomarker outcomes in patients with AQP4-IgG-seropositive neuromyelitis optica spectrum disorder receiving open-label satralizumab.
Bennett JL; Fujihara K; Kim HJ; Marignier R; O'Connor KC; Sergott RC; Traboulsee A; Wiendl H; Wuerfel J; Zamvil SS; Anania VG; Buffels R; Künzel T; Lekkerkerker AN; Lennon-Chrimes S; Pittock SJ
Front Neurol; 2023; 14():1114667. PubMed ID: 36873431
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar.
Yamamura T; Weinshenker B; Yeaman MR; De Seze J; Patti F; Lobo P; von Büdingen HC; Kou X; Weber K; Greenberg B
Mult Scler Relat Disord; 2022 Oct; 66():104025. PubMed ID: 36007339
[TBL] [Abstract][Full Text] [Related]
13. Satralizumab in the treatment of neuromyelitis optica spectrum disorder.
Duchow A; Bellmann-Strobl J
Neurodegener Dis Manag; 2021 Feb; 11(1):49-59. PubMed ID: 33167776
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of inebilizumab in Asian participants with neuromyelitis optica spectrum disorder: Subgroup analyses of the N-MOmentum study.
Fujihara K; Kim HJ; Saida T; Misu T; Nagano Y; Totsuka N; Iizuka M; Kido S; Terata R; Okumura K; Hirota S; Cree BAC
Mult Scler Relat Disord; 2023 Nov; 79():104938. PubMed ID: 37769428
[TBL] [Abstract][Full Text] [Related]
15. Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.
Pittock SJ; Berthele A; Fujihara K; Kim HJ; Levy M; Palace J; Nakashima I; Terzi M; Totolyan N; Viswanathan S; Wang KC; Pace A; Fujita KP; Armstrong R; Wingerchuk DM
N Engl J Med; 2019 Aug; 381(7):614-625. PubMed ID: 31050279
[TBL] [Abstract][Full Text] [Related]
16. Real-world management of patients with neuromyelitis optica spectrum disorder using satralizumab: Results from a Japanese claims database.
Nakashima I; Nakahara J; Yasunaga H; Yamashita M; Nishijima N; Satomura A; Nio M; Fujihara K
Mult Scler Relat Disord; 2024 Apr; 84():105502. PubMed ID: 38401202
[TBL] [Abstract][Full Text] [Related]
17. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.
Wolinsky JS; Arnold DL; Brochet B; Hartung HP; Montalban X; Naismith RT; Manfrini M; Overell J; Koendgen H; Sauter A; Bennett I; Hubeaux S; Kappos L; Hauser SL
Lancet Neurol; 2020 Dec; 19(12):998-1009. PubMed ID: 33129442
[TBL] [Abstract][Full Text] [Related]
18. [Local experience of IL-6 pathway inhibition with satralizumab for patients with neuromyelitis optica spectrum disorder].
Prakhova LN; Krasnov VS; Kasatkin DS; Korobko DS
Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(7. Vyp. 2):68-72. PubMed ID: 35912559
[TBL] [Abstract][Full Text] [Related]
19. Anti-IL-6 Therapies for Neuromyelitis Optica Spectrum Disorders: A Systematic Review of Safety and Efficacy.
Lotan I; McGowan R; Levy M
Curr Neuropharmacol; 2021; 19(2):220-232. PubMed ID: 32348222
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in the treatment of neuromyelitis optica spectrum disorders.
Romeo AR
Curr Opin Rheumatol; 2021 May; 33(3):233-239. PubMed ID: 33741809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
